Loading clinical trials...

Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients | Clinical Trials | Clareo Health

COMPLETED

Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

An Observational Study To Collect Follow-up Clinical Data From Kidney Transplant Recipients Who Received Tofacitinib (CP-690,550) In Completed Phase 2 Studies

NCT01375127•Pfizer

View on ClinicalTrials.gov

Summary

This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.

Detailed Description

Subjects are identified based on whether they received tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or who did not elect to enroll in long-term extension studies. Subjects are pre-identified

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects have discontinued tofacitinib prior to the planned treatment duration in 2 completed Phase 2 studies; or have not enrolled in long-term extension studies.

Exclusion Criteria

•No other subjects are eligible for this study

Locations (43)

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Palo Alto, California, United States

Pfizer Investigational Site

San Francisco, California, United States

Pfizer Investigational Site

San Francisco, California, United States

Pfizer Investigational Site

Stanford, California, United States

Pfizer Investigational Site

Aurora, Colorado, United States

Pfizer Investigational Site

Tampa, Florida, United States

Pfizer Investigational Site

Chicago, Illinois, United States

Pfizer Investigational Site

Chicago, Illinois, United States

Key Dates

Start Date

August 1, 2011

Primary Completion Date

July 1, 2012

Completion Date

July 1, 2012

Last Updated

October 29, 2013

Enrollment

ACTUAL participants

Conditions

Kidney Transplantation

Interventions

Tofacitinib

DRUG

Tofacitinib

DRUG

Parathyroidectomy After Kidney Transplantation

NCT07415421

HyperparathyroidismKidney Transplantation Recipients

View study

RECRUITINGPHASE4

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

NCT06958796

CytomegalovirusOrgan Transplant+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 29, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

Inclusion Criteria

Exclusion Criteria

Parathyroidectomy After Kidney Transplantation

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

Tolerance Through Mixed Chimerism (Sip-Tego)

Study of the Link Between Complement Activation and IgA Nephropathy Severity